Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Johnson & Johnson's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $68,774 Mil. Johnson & Johnson's Total Assets for the quarter that ended in Dec. 2023 was $167,558 Mil.
Therefore, Johnson & Johnson's Equity to Asset Ratio for the quarter that ended in Dec. 2023 was 0.41.
The historical rank and industry rank for Johnson & Johnson's Equity-to-Asset or its related term are showing as below:
JNJ'
s Equity-to-Asset Range Over the Past 10 Years
Min: 0.36 Med: 0.41 Max: 0.54
Current: 0.41
During the past 13 years, the highest Equity to Asset Ratio of Johnson & Johnson was 0.54. The lowest was 0.36. And the median was 0.41.
JNJ's Equity-to-Asset is ranked worse than 70.93% of 1087
companies
in the Drug Manufacturers industry
Industry Median: 0.59
vs JNJ: 0.41
Johnson & Johnson Equity-to-Asset Historical Data
The historical data trend for Johnson & Johnson's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Johnson & Johnson's Equity-to-Asset
For the Drug Manufacturers - General subindustry, Johnson & Johnson's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Johnson & Johnson's Equity-to-Asset Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Johnson & Johnson's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Johnson & Johnson's Equity-to-Asset falls into.
Johnson & Johnson Equity-to-Asset Calculation
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Johnson & Johnson's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Johnson & Johnson (NYSE:JNJ) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Johnson & Johnson Equity-to-Asset Related Terms
Thank you for viewing the detailed overview of Johnson & Johnson's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.
Johnson & Johnson (Johnson & Johnson) Business Description
Johnson & Johnson is the world's largest and most diverse healthcare firm. Three divisions make up the firm: pharmaceutical, medical devices and diagnostics, and consumer. The drug and device groups represent close to 80% of sales and drive the majority of cash flows for the firm. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. The device segment focuses on orthopedics, surgery tools, vision care, and a few smaller areas. The last segment of consumer focuses on baby care, beauty, oral care, over-the-counter drugs, and women's health. The consumer group is being divested in 2023 under the new name Kenvue. Geographically, just over half of total revenue is generated in the United States.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
JNJ has been successfully added to your 